Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for biotechnology industry professionals · Thursday, November 21, 2019 · 502,853,161 Articles · 3+ Million Readers

Selvita Ranked the No. 1 Rising Star in Deloitte Technology Fast 50 Central Europe

Kraków, Poland, October  18, 2011 / B3C newswire / - Selvita S.A. has been ranked as the no.1 Rising Star within this year’s contest of Deloitte Technology Fast 50 in Central Europe.

The Central Europe Technology Fast 50 program, is part of a global effort by Deloitte to identify the fastest growing technology companies all over the world, which became a recognized benchmark of success in the technology industry. This prestigious annual award honors the fastest growing Central European technology companies, based on the percentage of revenue growth over certain period of time.

In this year’s edition, Selvita was voted as the no. 1 Rising Star, meaning a young, emerging company with the most potential to grow. With the result of a 2 623% increase in revenues over the past three years, Selvita beat a long list of high technology companies from Albania, Bosnia & Herzegovina, Bulgaria, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Macedonia, Moldova, Poland, Romania, Serbia, Montenegro, Slovakia and Slovenia.

What’s more, Selvita is also the only biotechnology company which can be found in the ranking.

Pawel Przewiezlikowski, Selvita’s CEO, received the no 1 Rising Star award, during the official XII Deloitte Technology Fast 50 Central Europe, on 17th October 2011, in Warsaw, naming Selvita the most promising and fastest developing emerging company in Central Europe.

Read more: and

About Selvita
Selvita Group is an independent integrated drug discovery provider.  Selvita offers its clients services ranging from computational chemistry, through chemical development to preclinical in vitro research, done in-house. Company’s mission is to serve its clients with a comprehensive panel of products and solutions targeted at lowering the cost of, and accelerating the introduction of new drugs to the market. Since 2010, Selvita is the owner of BioCentrum, which provides in vitro preclinical ADMET services, analytical services and  biochemistry services with special focus on protein engineering and antibody development. Selvita' Group laboratories are certified with the Good Laboratory Practice (GLP) certificate, as well as have the accreditation of Polish General Pharmaceutical Inspectorate.

Media contact
Natalia Pawela
+48 12 297 47 31

Powered by EIN Presswire
Distribution channels: Technology

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release